
Pamiparib
CAS No. 1446261-44-4
Pamiparib( BGB-290 | BGB 290 )
Catalog No. M11894 CAS No. 1446261-44-4
Pamiparib (BGB-290, BGB290) is a?highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 36 | In Stock |
![]() ![]() |
5MG | 45 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NamePamiparib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPamiparib (BGB-290, BGB290) is a?highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.
-
DescriptionPamiparib (BGB-290, BGB290) is a?highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.Ovarian Cancer Phase 2 Clinical(In Vitro):Pamiparib shows potent DNA-trapping activity with an IC50 of 13 nM. In the cellular assays, Pamiparib inhibits intracellular PAR formation with an IC50 of 0.24 nM. Tumor cell lines with homologous recombination defects are profoundly sensitive to Pamiparib. Pamiparib is highly active both in vitro and in vivo in BRCA mutant tumors.(In Vivo):Pamiparib suppresses PARP activity in patient-derived glioblastoma multiforme and small-cell-lung cancer xenografts, and potentiates the effects of Temozolamide. In vivo activities of Pamiparib, and its combination activity with chemotherapies in patient biopsy derived small cell lung cancer (SCLC) xenograft models.
-
In VitroPamiparib shows potent DNA-trapping activity with an IC50 of 13 nM. In the cellular assays, Pamiparib inhibits intracellular PAR formation with an IC50 of 0.24 nM. Tumor cell lines with homologous recombination defects are profoundly sensitive to Pamiparib. Pamiparib is highly active both in vitro and in vivo in BRCA mutant tumors.
-
In VivoPamiparib suppresses PARP activity in patient-derived glioblastoma multiforme and small-cell-lung cancer xenografts, and potentiates the effects of Temozolamide. In vivo activities of Pamiparib, and its combination activity with chemotherapies in patient biopsy derived small cell lung cancer (SCLC) xenograft models.
-
SynonymsBGB-290 | BGB 290
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP
-
Research AreaCancer
-
IndicationOvarian Cancer
Chemical Information
-
CAS Number1446261-44-4
-
Formula Weight298.32
-
Molecular FormulaC16H15FN4O
-
Purity>98% (HPLC)
-
SolubilityDMSO : 83.3 mg/mL 279.24 mM
-
SMILESCC12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F
-
Chemical Name(10aR)-2-fluoro-10a-methyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11- tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
Fluzoparib
fluzoparib is a novel, potent, and orally available inhibitor of PARP, potentially for the treatment of solid tumours.Fluzoparib potently inhibited PARP1 enzyme activity and induced DNA double-strand breaks, G2 /M arrest, and apoptosis in homologous recombination repair (HR)-deficient cells.?
-
Rucaparib phosphate
An inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay.
-
NVP-BVU972
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.